The estimated Net Worth of Fredric N Eshelman Ventures... is at least $368 mil dollars as of 1 April 2022. Fredric Ventures owns over 4,545,455 units of Aravive Inc stock worth over $368,471 and over the last 4 years Fredric sold ARAV stock worth over $0.
Sign up
Fredric Ventures ARAV stock SEC Form 4 insiders trading
Fredric has made over 1 trades of the Aravive Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Fredric exercised 4,545,455 units of ARAV stock worth $181,818 on 1 April 2022.
The largest trade Fredric's ever made was exercising 4,545,455 units of Aravive Inc stock on 1 April 2022 worth over $181,818. On average, Fredric trades about 505,051 units every 0 days since 2020. As of 1 April 2022 Fredric still owns at least 9,211,769 units of Aravive Inc stock.
You can see the complete history of Fredric Ventures stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Aravive Inc
Over the last 6 years, insiders at Aravive Inc have traded over $107,045 worth of Aravive Inc stock and bought 151,333 units worth $1,102,898 . The most active insiders traders include Srinivas Akkaraju, Fredric N Eshelman Ventures... y Shahzad Malik. On average, Aravive Inc executives and independent directors trade stock every 75 days with the average trade being worth of $11,962. The most recent stock trade was executed by Fredric N Eshelman Ventures... on 1 April 2022, trading 4,545,455 units of ARAV stock currently worth $181,818.
What does Aravive Inc do?
versartis, inc. (nasdaq: vsar) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. the company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. versartis’ mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. learn more at www.versartis.com.
What does Aravive Inc's logo look like?
Complete history of Fredric Ventures stock trades at Aravive Inc
Aravive Inc executives and stock owners
Aravive Inc executives and other stock owners filed with the SEC include:
-
Gail McIntyre,
President, Chief Executive Officer, Director -
Vinay Shah,
Chief Financial Officer -
Dr. Gail F. McIntyre CH (ASCP), DABT, Ph.D.,
Pres, CEO & Director -
Dr. Reshma Rangwala M.D., Ph.D.,
Chief Medical Officer -
Amato Giaccia,
Independent Director -
Raymond Tabibiazar,
Independent Director -
Eric Zhang,
Independent Director -
Dr. Fredric N. Eshelman Pharm.D.,
Exec. Chairman -
Mike Zanoni,
IR Contact Officer -
Michael Rogers,
Director -
Reshma Rangwala,
Chief Medical Officer -
Fredric Eshelman,
Independent Chairman of the Board -
Kenneth L. Guernsey,
Sec. -
Dr. Randy L. Anderson,
Sr. VP of Data Sciences -
Joseph T. Schepers,
VP of Investor Relations -
Dr. Joshua Silverman Ph.D.,
Co-Founder -
Dr. Jeffrey L. Cleland,
Co-Founder -
Maria Carolina Petrini,
Chief Commercial Officer -
Robert B. Geller,
Chief Medical Officer -
Leonard Scott Dove,
Chief Operating Officer -
Rekha Hemrajani,
-
Srinivas Akkaraju,
Director -
Jay Shepard,
President and CEO -
Kevin Haas,
VP, Finance and PAO -
Shahzad Malik,
Director -
Robert Hoffman,
Director -
Peter Tai Ching Ho,
Director -
John Hohneker,
Director -
Sigurd Kirk,
Director -
Rudy Howard,
Chief Financial Officer